Premature Ejaculation (PE) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

 Premature Ejaculation (PE) Market Outlook

Thelansis’s “Premature Ejaculation (PE) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Premature Ejaculation (PE) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Premature Ejaculation (PE) Overview

In the male reproductive system, ejaculation refers to the release and external expression of semen. Premature ejaculation is a term used to describe the occurrence of ejaculation happening consistently earlier than desired by a man or his partner during sexual activity. This condition is recognized as the most prevalent male sexual disorder. Primarily of psychological origin, premature ejaculation’s precise cause remains largely unknown. Various contributing risk factors have been identified, encompassing biological and psychological aspects. Biological factors include abnormal levels of the brain neurotransmitter serotonin, abnormal hormonal levels, hypogonadism, inflammation or infection of the prostate or urethra, and erectile dysfunction. Psychological factors include depression, anxiety, stress, guilt, narcissism, distorted thinking, unrealistic expectations about sexual performance, performance anxiety, history of sexual repression, overall lack of confidence or poor body image, and history of sexual abuse or prior negative experiences. The control of ejaculation is regulated by the spinal ejaculatory generator center, located at the L1-L2 level. This center receives inputs from the penile nerves, both parasympathetic and sympathetic, and communicates through sensory and motor nerves. Alongside the spinal ejaculatory center, the central, spinal, and peripheral nervous systems collaboratively function for emission and ejaculation. A normal ejaculation is a complex but well-coordinated sequence of physiological events involving three phases: emission, expulsion, and orgasm. Before diagnosing premature ejaculation, other conditions must be considered, such as severely delayed orgasm in the female partner. The average time to reach climax in females is 12 to 25 minutes. In cases of extremely delayed female orgasm, almost any male would be perceived as experiencing premature ejaculation, making the partner’s sexual response a factor that necessitates evaluation. Common treatment options for premature ejaculation include behavioral techniques, medications, and counseling. Topical applications such as creams, gels, or sprays containing numbing agents like benzocaine, lidocaine, or prilocaine are used to alleviate premature ejaculation. These substances are applied to the penis 10 to 15 minutes before sexual activity to reduce sensation and delay ejaculation.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2024–2034)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: Premature Ejaculation (PE) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034